Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomerica (BMRA) Receivables (2016 - 2026)

Biomerica's Receivables history spans 16 years, with the latest figure at $1.9 million for Q1 2026.

  • On a quarterly basis, Receivables fell 25.07% to $1.9 million in Q1 2026 year-over-year; TTM through Feb 2026 was $1.9 million, a 25.07% decrease, with the full-year FY2025 number at $1.5 million, down 22.22% from a year prior.
  • Receivables hit $1.9 million in Q1 2026 for Biomerica, down from $2.0 million in the prior quarter.
  • Over the last five years, Receivables for BMRA hit a ceiling of $3.1 million in Q3 2024 and a floor of $754559.0 in Q1 2023.
  • Historically, Receivables has averaged $1.9 million across 5 years, with a median of $1.9 million in 2026.
  • Biggest five-year swings in Receivables: plummeted 54.6% in 2022 and later soared 202.56% in 2024.
  • Tracing BMRA's Receivables over 5 years: stood at $850014.0 in 2022, then surged by 153.64% to $2.2 million in 2023, then grew by 24.26% to $2.7 million in 2024, then decreased by 25.72% to $2.0 million in 2025, then decreased by 3.57% to $1.9 million in 2026.
  • Business Quant data shows Receivables for BMRA at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.5 million in Q3 2025.